Role of intensity-modulated radiation therapy in gastrointestinal cancer

References

• Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer110(10), 2191–2201 (2007).
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrans RA, et al.Fluorouracil vs. gemcitabine chemotherapy before and after fluroouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA299(9), 1019–1026 (2008).
   PubMed Web of Science ®Google Scholar
• Herman J, Swartz M, Hsu C et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas; results of a large, prospectively collected database at the Johns Hopkins hospital. J. Clin. Oncol.2, 3503–3510 (2008).
   Google Scholar
• Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med.350(12), 1200–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Spalding AC, Jee KW, Vineberg K et al. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med. Phys.34(2), 521–529 (2007).
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Lawrence TS. Chemoradiotherapy for unresectable pancreatic cancer. Int. J. Clin. Oncol.13(2), 121–126 (2008).
   PubMedGoogle Scholar
• Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys.21, 109–122 (1991).
   PubMed Web of Science ®Google Scholar
• Chmura SJ, Heimann R. Normal tissue toxicity using intensity modulated radiation therapy (IMRT) in pancreatic cancer and cholangiocarcinoma. Proc. Am. Soc. Clin. Oncol.20 (2001) (Abstract 1093).
   Google Scholar
• Landry JC, Esiashvili N, Ting JY, Staley C. Intensity modulated radiation therapy employing the volume at risk approach to minimize small bowel and renal toxicity when treating patients with locally advanced pancreatic carcinomas. Int. J. Radiat. Oncol. Biol. Phys.51(3), 270 (2001).
   Google Scholar
• Brown MW, Ning H, Arora B et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys.65(1), 274–283 (2006).
   PubMedGoogle Scholar
• Crane CH, Antolak JA, Rosen II et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int. J. Gastroint. Cancer30(3), 123–132 (2001).
   PubMedGoogle Scholar
• Bai YR, Wu GH, Wu XD et al. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. World J. Gastroenterol.9(11), 2561–2564 (2003).
   PubMed Web of Science ®Google Scholar
• Milano MT, Chmura SJ, Garofalo MC et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int. J. Radiat. Oncol. Biol. Phys.59(2), 445–453 (2004).
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Shields AF, Vaishampayan U et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys.59(2), 454–459 (2004).
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med.345(10), 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med.355(1), 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter K, Okawara GS et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J. Clin. Oncol.24(24), 3953–3958 (2006).
   PubMed Web of Science ®Google Scholar
• Caudry M, Ratoanina JL, Escarmant P, Maire JP. Target volume in radiotherapy of gastric adenocarcinoma. Cancer Radiother.5, 523–533 (2001).
   PubMedGoogle Scholar
• Wieland P, Dobler B, Mai S et al. IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int. J. Radiat. Oncol. Biol. Phys.59(4), 1236–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Ringash J, Perkins G, Brierley J et al. IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int. J. Radiat. Oncol. Biol. Phys.63(3), 732–738 (2005).
   PubMed Web of Science ®Google Scholar
• Milano MT, Garofalo MC, Chmura SJ et al. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br. J. Radiol.79(942), 497–503 (2006).
   PubMed Web of Science ®Google Scholar
• Kataria T, Rawat S, Sinha SN et al. Intensity modulated radiotherapy in abdominal malignancies: our experience in reducing the dose to normal structures as compared to the gross tumor. J. Cancer. Res. Ther.2(4), 161–165 (2006).
   PubMedGoogle Scholar
• Minsky BD, Cohen AM, Enker WE et al. Preoperative 5-FU, low dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.37, 289–295 (1997).
   PubMedGoogle Scholar
• Janjan NA, Khoo VS, Abbruzzeese J et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. Int. J. Radiat. Oncol. Biol. Phys.44, 1027–1038 (1999).
   PubMed Web of Science ®Google Scholar
• Gunnlaugsson A, Kjellen E, Nilsson P et al. Dose–volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncologic46, 937–944 (2007).
   PubMed Web of Science ®Google Scholar
• Robertson JM, Lockman D, Yan D, Wallace M. The dose–volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.70(2), 413–418 (2008).
   PubMed Web of Science ®Google Scholar
• Mak AC, Rich TA, Schultheiss TE et al. Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid. Int. J. Radiat. Oncol. Biol. Phys.28, 597–603 (1994).
   PubMed Web of Science ®Google Scholar
• Duthoy W, De Gersem W, Vergote K et al. Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.60(3), 794–806 (2004).
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, Robertson JM, Yan D, Martinez A. The influence of small bowel motion on both a conventional three-field and intensity modulated radiation therapy (IMRT) for rectal cancer. Cancer Radiother.8(5), 297–304 (2004).
   PubMedGoogle Scholar
• Tho LM, Glegg M, Paterson J et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int. J. Radiat. Oncol. Biol. Phys.66(2), 505–513 (2006).
   PubMed Web of Science ®Google Scholar
• Ballonoff A, Kavanagh B, McCarter M et al. Operative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a Phase II trial. Am. J. Clin. Oncol.31(3), 264–270 (2008).
   PubMed Web of Science ®Google Scholar
• Chmura SJ, Kim S, Johnson S et al. Intensity modulated radiation therapy (IMRT) in anal cancer. Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 2358).
   Google Scholar
• Chen YJ, Liu A, Tsai PT et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int. J. Radiat. Oncol. Biol. Phys.63(1), 274–281 (2005).
   PubMed Web of Science ®Google Scholar
• Chmura SJ, Milano M, Garofalo M et al. Initial outcome with intensity-modulated radiation (IMRT) and chemotherapy (CTX) in anal cancer. Proc. Am. Soc. Clin. Oncol.22, 368 (2003).
   Google Scholar
• Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int. J. Radiat. Oncol. Biol. Phys.63(2), 354–361 (2005).
   PubMed Web of Science ®Google Scholar
• Salama JK, Mell LK, Schomas DA et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J. Clin. Oncol.25(29), 4581–4586 (2007).
   PubMed Web of Science ®Google Scholar
• Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int. J. Radiat. Oncol. Biol. Phys.71(5), 1504–1510 (2008).
   PubMed Web of Science ®Google Scholar
• Menkarios C, Azria D, Laliberté B et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat. Oncol.2, 41 (2007).
   PubMedGoogle Scholar
• Guerrero Urbano MT, Henrys AJ, Adams EJ et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int. J. Radiat. Oncol. Biol. Phys.65(3), 907–916 (2006).
   PubMedGoogle Scholar
• Kim JY, Kim DY, Kim TH et al. Intensity-modulated radiotherapy with a belly board for rectal cancer. Int. J. Colorectal Dis.22(4), 373–379 (2007).
   PubMed Web of Science ®Google Scholar